Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Dec. 31, 2011	Dec. 31, 2010
Current Assets:
Cash and equivalents	$ 121,202	$ 53,557
Marketable securities	40,060	42,117
Accounts receivable, net of allowance for doubtful accounts of $471 and $339, respectively	51,703	21,051
Inventories, net	10,762	4,234
Prepaid expenses and other current assets	2,074	906
Total current assets	225,801	121,865
Investments	9,283	8,569
Property and equipment, net	2,681	3,158
Intangible assets, net	41,654	29,605
Other assets	1,361	434
Total assets	280,780	163,631
Current Liabilities:
Accounts payable and other accrued obligations	54,771	38,704
Accrued compensation and related expenses	1,788	3,313
Deferred revenue	12,300	12,300
Common stock warrant liability	0	3,904
Accrued drug development costs	9,678	5,101
Total current liabilities	78,537	63,322
Capital lease obligations	9	40
Deferred revenue and other credits - less current portion	14,029	25,495
Other long-term obligations	298	298
Total liabilities	92,873	89,155
Commitments and contingencies
Preferred stock, $0.001 par value; 5,000,000 shares authorized:
Common stock, $0.001 par value - 175,000,000 shares authorized; 59,247,483 and 51,459,284 issued and outstanding at December 31, 2011 and 2010, respectively	59	51
Additional paid-in capital	452,761	384,757
Accumulated other comprehensive loss	(227)	(92)
Accumulated deficit	(261,883)	(310,400)
Less: Treasury stock at cost: 363,055 shares at December 31, 2011	(2,926)	0
Total stockholders' equity	187,907	74,476
Total liabilities and stockholders' equity	280,780	163,631
Series B Junior participating preferred stock
Preferred stock, $0.001 par value; 5,000,000 shares authorized:
Preferred stock value
Series E convertible voting preferred stock
Preferred stock, $0.001 par value; 5,000,000 shares authorized:
Preferred stock value	$ 123	$ 160